C4 Therapeutics is on a roll in finding partners to advance its protein degradation platform, signing a deal with Merck KGaA to develop two oncology assets.
The collaboration will center on two preclinical targeted protein degraders against critical oncogenic proteins, and C4 Therapeutics will receive an...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?